Phlexglobal has announced its expansion across the United States with the opening of an office in Philadelphia, Pennsylvania.
Phlexglobal’s expansion across the US follows the success enjoyed by the organization’s California office which has seen exponential demand for its services across the North American territory.
The opening of the Philadelphia office comes hot on the heels of April’s management buy out (MBO) of the company by UK private equity firm Inflexion, which will allow Phlexglobal to further expand its provision of clinical trial support, underpinned by the recent launch of version 3 of the company’s eTMF solution, PhlexEview.
The new East Coast office, which will deliver all Phlexglobal’s TMF services including the PhlexEview eTMF solution, will initially employ 20 staff, growing to 50 employees within the first year of operation.
In addition to providing a base for Phlexglobal’s resource solutions and operations task force, the 800 square metre office will also house a new records centre, securely storing live TMF documents for Phlexglobal clients across the United States.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.